PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
Abstract Pancreatic cancer is a highly lethal disease with a poor prognosis, and existing therapies offer only limited effectiveness. Mutation gene sequencing has shown several gene associations that may account for its carcinogenesis, revealing a promising research direction. Poly (ADP-ribose) poly...
Main Authors: | Heng Zhu, Miaoyan Wei, Jin Xu, Jie Hua, Chen Liang, Qingcai Meng, Yiyin Zhang, Jiang Liu, Bo Zhang, Xianjun Yu, Si Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12943-020-01167-9 |
Similar Items
-
Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
by: Yongsong Wu, et al.
Published: (2023-01-01) -
Pharmacologic Induction of BRCAness in <i>BRCA</i>-Proficient Cancers: Expanding PARP Inhibitor Use
by: Rachel Abbotts, et al.
Published: (2022-05-01) -
Resistance to PARP-inhibitors in Cancer Therapy
by: Alicia eMontoni, et al.
Published: (2013-02-01) -
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
by: Jaromir Hunia, et al.
Published: (2022-12-01) -
PARP inhibitors in metastatic prostate cancer
by: Amy K. Taylor, et al.
Published: (2023-04-01)